These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 2898457)

  • 1. The effects of a new beta-adrenoceptor agonist BRL 26830A in refractory obesity.
    Chapman BJ; Farquahar DL; Galloway SM; Simpson GK; Munro JF
    Int J Obes; 1988; 12(2):119-23. PubMed ID: 2898457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical studies with the beta-adrenoceptor agonist BRL 26830A.
    Connacher AA; Bennet WM; Jung RT
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):258S-261S. PubMed ID: 1345890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of obesity with thermogenic beta-adrenoceptor agonists: studies on BRL 26830A in rodents.
    Arch JR; Ainsworth AT; Ellis RD; Piercy V; Thody VE; Thurlby PL; Wilson C; Wilson S; Young P
    Int J Obes; 1984; 8 Suppl 1():1-11. PubMed ID: 6152555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight loss in obese subjects on a restricted diet given BRL 26830A, a new atypical beta adrenoceptor agonist.
    Connacher AA; Jung RT; Mitchell PE
    Br Med J (Clin Res Ed); 1988 Apr; 296(6631):1217-20. PubMed ID: 2898268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tremor and the anti-obesity drug BRL 26830A.
    Connacher AA; Lakie M; Powers N; Elton RA; Walsh EG; Jung RT
    Br J Clin Pharmacol; 1990 Oct; 30(4):613-5. PubMed ID: 1981320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic administration of BRL 26830A for 9 weeks improves insulin sensitivity but does not prevent weight gain in gold-thioglucose obese mice.
    Bryson JM; Wensley VR; Phuyal JL; Caterson ID; Cooney GJ
    Horm Metab Res; 1999 May; 31(5):317-22. PubMed ID: 10422727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of novel beta-adrenoceptor agonists on carbohydrate metabolism: relevance for the treatment of non-insulin-dependent diabetes.
    Cawthorne MA; Carroll MJ; Levy AL; Lister CA; Sennitt MV; Smith SA; Young P
    Int J Obes; 1984; 8 Suppl 1():93-102. PubMed ID: 6152558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychological aspects of dietary weight loss and medication with the atypical beta agonist BRL 26830A in obese subjects.
    MacLachlan M; Connacher AA; Jung RT
    Int J Obes; 1991 Jan; 15(1):27-35. PubMed ID: 1672679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thermogenic and antiobesity activity of a novel beta-adrenoceptor agonist (BRL 26830A) in mice and rats.
    Arch JR; Ainsworth AT
    Am J Clin Nutr; 1983 Oct; 38(4):549-58. PubMed ID: 6137948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate supply for thermogenesis induced by the beta-adrenoceptor agonist BRL 26830A.
    Wilson S; Thurlby PL; Arch JR
    Can J Physiol Pharmacol; 1987 Feb; 65(2):113-9. PubMed ID: 2882828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic effects of three weeks administration of the beta-adrenoceptor agonist BRL 26830A.
    Connacher AA; Bennet WM; Jung RT; Rennie MJ
    Int J Obes Relat Metab Disord; 1992 Sep; 16(9):685-94. PubMed ID: 1356939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitigation of obesity by BRL 26830A, a new beta-adrenoceptor agonist, in MSG obese mice.
    Yoshida T; Yoshioka K; Kamanaru K; Hiraoka N; Kondo M
    J Nutr Sci Vitaminol (Tokyo); 1990 Feb; 36(1):75-80. PubMed ID: 1972962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-obesity and anti-diabetic actions of a beta 3-adrenoceptor agonist, BRL 26830A, in yellow KK mice.
    Yoshida T; Hiraoka N; Yoshioka K; Hasegawa G; Kondo M
    Endocrinol Jpn; 1991 Aug; 38(4):397-403. PubMed ID: 1687027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antidiabetic beta 3-adrenoceptor agonist BRL 26830A works by release of endogenous insulin.
    Yoshida T
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):237S-241S. PubMed ID: 1345886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRL 26830A and weight loss.
    Munro JF; Donald P; Chapman BJ; Farquhar DL; Rhein H
    Br Med J (Clin Res Ed); 1988 Jun; 296(6638):1737-8. PubMed ID: 2900042
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of a beta 3-adrenoceptor agonist, BRL 26830A, on insulin and glucagon release in mice.
    Yoshida T; Hiraoka N; Kondo M
    Endocrinol Jpn; 1991 Dec; 38(6):641-6. PubMed ID: 1688048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The alpha/beta-adrenergic receptor blocker arotinolol activates the thermogenesis of brown adipose tissue in monosodium-L-glutamate-induced obese mice.
    Yoshida T; Sakane N; Wakabayashi Y; Yoshioka K; Umekawa T; Kondo M
    Int J Obes Relat Metab Disord; 1994 May; 18(5):339-43. PubMed ID: 7520314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a novel beta-adrenoceptor agonist (Ro 40-2148) on resting energy expenditure in obese women.
    Haesler E; Golay A; Güzelhan C; Schutz Y; Hartmann D; Jéquier E; Felber JP
    Int J Obes Relat Metab Disord; 1994 May; 18(5):313-22. PubMed ID: 7914795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRL 35135, a potent and selective atypical beta-adrenoceptor agonist.
    Cawthorne MA; Sennitt MV; Arch JR; Smith SA
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):252S-257S. PubMed ID: 1345889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.